Which blood thinner costs less for cancer patients with clots? study investigates.
NCT ID NCT05643885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical costs for cancer patients who had a blood clot (VTE) and were treated with either apixaban or low molecular weight heparin. Researchers analyzed insurance claims from over 7,300 patients to compare total healthcare costs, including hospital stays and pharmacy bills. The goal was to see which treatment might be more affordable for patients and the healthcare system.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Investigational
New York, New York, 10017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?